These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209 [TBL] [Abstract][Full Text] [Related]
9. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib. Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030 [TBL] [Abstract][Full Text] [Related]
10. Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib? Keizman D; Rouvinov K; Sella A; Gottfried M; Maimon N; Kim JJ; Eisenberger MA; Sinibaldi V; Peer A; Carducci MA; Mermershtain W; Leibowitz-Amit R; Weitzen R; Berger R Cancer Res Treat; 2016 Jan; 48(1):281-7. PubMed ID: 25761478 [TBL] [Abstract][Full Text] [Related]
11. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma. Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562 [TBL] [Abstract][Full Text] [Related]
12. Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. Keizman D; Gottfried M; Ish-Shalom M; Maimon N; Peer A; Neumann A; Hammers H; Eisenberger MA; Sinibaldi V; Pili R; Hayat H; Kovel S; Sella A; Boursi B; Weitzen R; Mermershtain W; Rouvinov K; Berger R; Carducci MA Oncologist; 2014 Jan; 19(1):51-60. PubMed ID: 24309979 [TBL] [Abstract][Full Text] [Related]
13. Statins and survival outcomes in patients with metastatic renal cell carcinoma. McKay RR; Lin X; Albiges L; Fay AP; Kaymakcalan MD; Mickey SS; Ghoroghchian PP; Bhatt RS; Kaffenberger SD; Simantov R; Choueiri TK; Heng DY Eur J Cancer; 2016 Jan; 52():155-62. PubMed ID: 26687834 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials. Sorich MJ; Kichenadasse G; Rowland A; Woodman RJ; Mangoni AA Int J Cancer; 2016 May; 138(9):2293-9. PubMed ID: 26685869 [TBL] [Abstract][Full Text] [Related]
16. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma. Shirotake S; Yasumizu Y; Ito K; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Tanaka N; Mizuno R; Oya M Clin Genitourin Cancer; 2016 Dec; 14(6):e575-e583. PubMed ID: 27102405 [TBL] [Abstract][Full Text] [Related]
17. The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. Basappa NS; Elson P; Golshayan AR; Wood L; Garcia JA; Dreicer R; Rini BI Cancer; 2011 Mar; 117(6):1183-9. PubMed ID: 20960527 [TBL] [Abstract][Full Text] [Related]
18. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors. Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995 [TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259 [TBL] [Abstract][Full Text] [Related]
20. Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration. Bamias A; Tzannis K; Beuselinck B; Oudard S; Escudier B; Diosynopoulos D; Papazisis K; Lang H; Wolter P; de Guillebon E; Stravodimos K; Chrisofos M; Fountzilas G; Elaidi RT; Dimopoulos MA; Bamia C Br J Cancer; 2013 Jul; 109(2):332-41. PubMed ID: 23807171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]